Valproic Acid
Medium/Large Size Posterior Uveal Melanoma
Explore 2 assets in Medium/Large Size Posterior Uveal Melanoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02068586CT.gov Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Medium/Large Size Posterior Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Valproic Acid (this asset) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC · 52 |
| Tyrosinase Peptide | National Cancer Institute (NCI) | P3 | BB |
| Sargramostim | National Cancer Institute (NCI) | P3 | BB |
| Dacarbazine | National Cancer Institute (NCI) | P2 | B |
| Ifa | National Cancer Institute (NCI) | P2 | B |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| gp100 antigen | National Cancer Institute (NCI) | P2 | B |
| Montanide Isa 51 | National Cancer Institute (NCI) | P2 | B |
| Cediranib | National Cancer Institute (NCI) | P2 | B |
+13 more in the Medium/Large Size Posterior Uveal Melanoma cohort
Other indications for Valproic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Disorder | — | P4 | BBB · 73 |
| Epilepsy | — | P4 | BBB · 73 |
| Bipolar I Disorder | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Valproic Acid in Medium/Large Size Posterior Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/valproic-acid-mediumlarge-size-posterior-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →